247 related articles for article (PubMed ID: 24738161)
1. Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women.
Monsen TJ; Holm SE; Ferry BM; Ferry SA
APMIS; 2014 Apr; 122(4):317-23. PubMed ID: 24738161
[TBL] [Abstract][Full Text] [Related]
2. [Urinary tract pathogens in uncomplicated lower urinary tract infections in women in Norway].
Jureen R; Digranes A; Baerheim A
Tidsskr Nor Laegeforen; 2003 Aug; 123(15):2021-2. PubMed ID: 12934120
[TBL] [Abstract][Full Text] [Related]
3. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.
Ferry SA; Holm SE; Stenlund H; Lundholm R; Monsen TJ
Scand J Prim Health Care; 2007 Mar; 25(1):49-57. PubMed ID: 17354160
[TBL] [Abstract][Full Text] [Related]
4. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
6. Pivmecillinam in treatment of Staphylococcus saprophyticus urinary tract infections.
Granlund M; Landgren E; Henning C
Scand J Infect Dis; 1983; 15(1):65-9. PubMed ID: 6302831
[TBL] [Abstract][Full Text] [Related]
7. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
8. Nalidixic acid and pivmecillinam for treatment of acute lower urinary tract infections.
Hovelius B; Mårdh PA; Nygaard-Pedersen L; Wathne B
Scand J Prim Health Care; 1985 Nov; 3(4):227-32. PubMed ID: 4081404
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women.
Duployez C; Loiez C; Cattoen C; Descamps D; Wallet F; Vachée A;
Med Mal Infect; 2016 Dec; 46(8):436-441. PubMed ID: 27609597
[TBL] [Abstract][Full Text] [Related]
10. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
[TBL] [Abstract][Full Text] [Related]
11. [Prescriptions of a new antibiotic following treatment with sulfamethizole or pivmecillinam].
Bjerrum L; Dessau RB; Hallas J
Ugeskr Laeger; 2003 Sep; 165(39):3732-5. PubMed ID: 14558387
[No Abstract] [Full Text] [Related]
12. Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.
Bjerrum L; Gahrn-Hansen B; Grinsted P
Scand J Prim Health Care; 2009; 27(1):6-11. PubMed ID: 18991182
[TBL] [Abstract][Full Text] [Related]
13. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
[TBL] [Abstract][Full Text] [Related]
14. [In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany].
Kresken M; Körber-Irrgang B; Naber KG
Aktuelle Urol; 2017 May; 48(3):243-247. PubMed ID: 28427111
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).
Zhanel GG; Hisanaga TL; Laing NM; DeCorby MR; Nichol KA; Palatnik LP; Johnson J; Noreddin A; Harding GK; Nicolle LE; Hoban DJ;
Int J Antimicrob Agents; 2005 Nov; 26(5):380-8. PubMed ID: 16243229
[TBL] [Abstract][Full Text] [Related]
16. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
Bollestad M; Grude N; Solhaug S; Raffelsberger N; Handal N; Nilsen HS; Romstad MR; Emmert A; Tveten Y; Søraas A; Jenum PA; Jenum S; Møller-Stray J; Weme ET; Lindbaek M; Simonsen GS;
J Antimicrob Chemother; 2018 Sep; 73(9):2503-2509. PubMed ID: 29982514
[TBL] [Abstract][Full Text] [Related]
17. Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient.
Nielsen KL; Hansen KH; Nielsen JB; Knudsen JD; Schønning K; Frimodt-Møller N; Hertz FB; Jansåker F
Microbiologyopen; 2019 Dec; 8(12):e941. PubMed ID: 31573735
[TBL] [Abstract][Full Text] [Related]
18. Pivmecillinam in the treatment of urinary tract infections.
Nicolle LE
J Antimicrob Chemother; 2000 Sep; 46 Suppl 1():35-9; discussion 63-5. PubMed ID: 11051622
[TBL] [Abstract][Full Text] [Related]
19. Uncomplicated urinary tract infections. Bacterial findings and efficacy of empirical antibacterial treatment.
Grude N; Tveten Y; Jenkins A; Kristiansen BE
Scand J Prim Health Care; 2005 Jun; 23(2):115-9. PubMed ID: 16036551
[TBL] [Abstract][Full Text] [Related]
20. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women.
Nicolle LE; Madsen KS; Debeeck GO; Blochlinger E; Borrild N; Bru JP; Mckinnon C; O'Doherty B; Spiegel W; Van Balen FA; Menday P
Scand J Infect Dis; 2002; 34(7):487-92. PubMed ID: 12195873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
